Aerocrine’s FeNO Technology is Standard Practice in NHANES Data by the CDC to Define Airway Inflammation in US Population
12/5/2011 6:15:08 AM
SOLNA, Sweden--(BUSINESS WIRE)--Regulatory News:
Aerocrine (STO:AEROB) announced that the Center for Disease Control for Health Statistics measured FeNO as a standard practice in examining the components on respiratory health, using the NIOX MINO device.
Aerocrine is very pleased the Centers for Disease Control and Prevention (CDC), through its National Center for Health Statistics, has recognized the importance of utilizing fractional exhaled nitric oxide (FeNO) measurements in a national survey to help understand the prevalence of airway inflammation in the U.S. population. The National Health and Nutrition Examination Survey (NHANES; http://www.cdc.gov/nchs/nhanes.htm), a continuous program with an evolving, need-based focus on a variety of health and nutrition measurements, is used to determine the prevalence of major diseases and risk factors for diseases.